Several other research firms have also recently weighed in on DBVT. Zacks Investment Research cut shares of DBV TECHNOLOGIE/S from a buy rating to a hold rating in a research report on Tuesday, August 6th. Goldman Sachs Group initiated coverage on shares of DBV TECHNOLOGIE/S in a research report on Monday, June 17th. They set a buy rating and a $14.00 price objective for the company. Finally, ValuEngine raised shares of DBV TECHNOLOGIE/S from a hold rating to a buy rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $14.81.
NASDAQ:DBVT opened at $8.98 on Thursday. DBV TECHNOLOGIE/S has a 1-year low of $3.60 and a 1-year high of $25.77. The company has a current ratio of 3.34, a quick ratio of 3.30 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $9.63 and a 200 day simple moving average of $8.78. The stock has a market capitalization of $528.97 million, a PE ratio of -2.65 and a beta of 1.82.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Further Reading: CD Ladder
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.